RU2187301C2 - Капсула для клеток, продуцирующих вирусные частицы, способ ее получения и использования - Google Patents

Капсула для клеток, продуцирующих вирусные частицы, способ ее получения и использования Download PDF

Info

Publication number
RU2187301C2
RU2187301C2 RU98101362/13A RU98101362A RU2187301C2 RU 2187301 C2 RU2187301 C2 RU 2187301C2 RU 98101362/13 A RU98101362/13 A RU 98101362/13A RU 98101362 A RU98101362 A RU 98101362A RU 2187301 C2 RU2187301 C2 RU 2187301C2
Authority
RU
Russia
Prior art keywords
capsule
cells
sulfate
viral particles
retroviral
Prior art date
Application number
RU98101362/13A
Other languages
English (en)
Russian (ru)
Other versions
RU98101362A (ru
Inventor
Роберт Михель Заллер
Вальтер Х. Гюнцбург
Брайан САЛМОНС
Original Assignee
Бавариан Нордик А/С
ГСФ-Форшунгсцентрум фюр Умвельт унд Гезундхайт ГмбХ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8097001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2187301(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бавариан Нордик А/С, ГСФ-Форшунгсцентрум фюр Умвельт унд Гезундхайт ГмбХ filed Critical Бавариан Нордик А/С
Publication of RU98101362A publication Critical patent/RU98101362A/ru
Application granted granted Critical
Publication of RU2187301C2 publication Critical patent/RU2187301C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
RU98101362/13A 1995-06-27 1996-06-24 Капсула для клеток, продуцирующих вирусные частицы, способ ее получения и использования RU2187301C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0740/95 1995-06-27
DK74095 1995-06-27

Publications (2)

Publication Number Publication Date
RU98101362A RU98101362A (ru) 1999-12-10
RU2187301C2 true RU2187301C2 (ru) 2002-08-20

Family

ID=8097001

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98101362/13A RU2187301C2 (ru) 1995-06-27 1996-06-24 Капсула для клеток, продуцирующих вирусные частицы, способ ее получения и использования

Country Status (21)

Country Link
US (1) US6776985B1 (2)
EP (1) EP0835137B1 (2)
JP (2) JP4119952B2 (2)
KR (1) KR100484883B1 (2)
CN (1) CN1187095C (2)
AT (1) ATE309000T1 (2)
AU (1) AU708273B2 (2)
CA (1) CA2222559A1 (2)
CZ (1) CZ286979B6 (2)
DE (1) DE69633180D1 (2)
DK (1) DK0835137T3 (2)
ES (1) ES2253754T3 (2)
IL (1) IL122119A (2)
NO (1) NO321427B1 (2)
NZ (1) NZ312671A (2)
PL (1) PL185338B1 (2)
PT (1) PT835137E (2)
RU (1) RU2187301C2 (2)
SI (1) SI0835137T1 (2)
UA (1) UA65525C2 (2)
WO (1) WO1997001357A1 (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2688383C2 (ru) * 2017-07-10 2019-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Способ синтеза белка в культуре бактериальных клеток
RU2749717C2 (ru) * 2015-11-24 2021-06-16 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способ временной трансфекции для продуцирования ретровируса
RU2752498C2 (ru) * 2015-11-24 2021-07-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Стабильные клеточные линии для продуцирования ретровирусов

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3908274B2 (ja) 1995-03-09 2007-04-25 ゲーエスエフ−フォルシュンクスツェントラム・フュア・ウムベルト・ウント・ゲズントハイト・ゲーエムベーハー 遺伝子治療用の抗菌ペプチドをコードする治療用遺伝子を有するベクター
ATE309000T1 (de) 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
US6540995B1 (en) 1996-03-27 2003-04-01 Bavarian Nordic Research Institute Gmbh Encapsulated cells producing cytochrome P450
RU2185821C2 (ru) 1996-03-27 2002-07-27 Бавариан Нордик Рисерч Инститьют А/С Трансдуцирующие цитохром р450 ретровирусные векторы
WO1999056660A1 (en) 1998-05-05 1999-11-11 Koninklijke Philips Electronics N.V. Toothbrush comprising a brush member having a bristle field and an interdental bristle field
AU2005229434B2 (en) 2004-03-30 2010-09-30 Nsgene A/S Therapeutic use of a growth factor, NsG33
JP2008540347A (ja) 2005-05-03 2008-11-20 フェテリネールメディツィニシュ ウニベルジテート ウィーン 浸透性カプセル
CN101903049B (zh) 2007-12-20 2014-08-13 伊西康公司 包囊的肾组织
KR101250925B1 (ko) * 2011-10-28 2013-04-04 한화케미칼 주식회사 캡슐 세포용 구조체
GB201408233D0 (en) 2014-05-09 2014-06-25 Austrianova Singapore Pte Ltd Use of polyanionic composition
US11427809B2 (en) 2016-05-25 2022-08-30 Lonza Houston, Inc. Methods for isolating adeno-associated virus using a polydialkylammonium salt
CA3220737A1 (en) * 2021-05-21 2022-11-24 Bionaut Labs Ltd. System and method for localized therapeutic treatment
CN115820683B (zh) * 2022-09-28 2024-04-05 西南大学 家蚕Cyp9a20基因及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
GB2135954A (en) * 1980-11-14 1984-09-12 Akad Wissenschaften Ddr Microcapsules and process for the production thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686098A (en) * 1984-05-14 1987-08-11 Merck & Co., Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
EP0199362A3 (en) * 1985-04-26 1987-10-07 Massachusetts Institute Of Technology System and apparatus for delayed and pulsed release of biologically active substances
CA1310924C (en) * 1986-04-24 1992-12-01 Francis P. Mccormick Infective drug delivery system
WO1989011539A1 (en) 1988-05-17 1989-11-30 Sloan-Kettering Institute For Cancer Research Retroviral vector
US5328470A (en) * 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE4021050A1 (de) * 1990-06-29 1992-01-02 Akad Wissenschaften Ddr Verfahren zur herstellung von mikrokapseln
CA2051288C (en) * 1990-09-14 2002-02-05 Robert L. Martuza Viral targeted destruction of neoplastic cells
WO1992010564A1 (en) * 1990-12-13 1992-06-25 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Sustained and continuous production of high titers of recombinant viral vectors and transduced target cells for use in gene therapy
WO1994029437A1 (en) 1993-06-07 1994-12-22 University Of Medicine & Dentistry Of New Jersey Highly-efficient, self-inactivating, recombination-free, u3-free retroviral vectors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
CA2198210C (en) 1994-09-02 2006-07-11 Gsf - Forschungszentrum Fur Umwelt Und Gesundheit Gmbh Non self-inactivating, expression targeted retroviral vectors
ATE309000T1 (de) 1995-06-27 2005-11-15 Bavarian Nordic As Verkapselte zellen die virenpartikeln produzieren
DK0848757T3 (da) 1995-09-06 2002-07-01 Austrian Nordic Biotherapeutic Anvendelse af WAP eller MMTV regulatoriske sekvenser for målrettet ekspression af sammenkædede heterologe gener i humane mammae celler, inklusiv humane mammae carcinoma celler
RU2185821C2 (ru) 1996-03-27 2002-07-27 Бавариан Нордик Рисерч Инститьют А/С Трансдуцирующие цитохром р450 ретровирусные векторы

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391909A (en) * 1979-03-28 1983-07-05 Damon Corporation Microcapsules containing viable tissue cells
GB2135954A (en) * 1980-11-14 1984-09-12 Akad Wissenschaften Ddr Microcapsules and process for the production thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2749717C2 (ru) * 2015-11-24 2021-06-16 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Способ временной трансфекции для продуцирования ретровируса
RU2752498C2 (ru) * 2015-11-24 2021-07-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Стабильные клеточные линии для продуцирования ретровирусов
RU2688383C2 (ru) * 2017-07-10 2019-05-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Саратовский национальный исследовательский государственный университет имени Н.Г. Чернышевского" Способ синтеза белка в культуре бактериальных клеток

Also Published As

Publication number Publication date
PL185338B1 (pl) 2003-04-30
EP0835137B1 (en) 2005-11-09
AU6415496A (en) 1997-01-30
IL122119A (en) 2004-06-01
ES2253754T3 (es) 2006-06-01
KR19990028491A (ko) 1999-04-15
NZ312671A (en) 1999-10-28
DK0835137T3 (da) 2006-03-06
KR100484883B1 (ko) 2005-09-02
CZ419597A3 (cs) 1998-03-18
CZ286979B6 (en) 2000-08-16
HK1010139A1 (en) 1999-06-17
JPH11508768A (ja) 1999-08-03
AU708273B2 (en) 1999-07-29
CN1187095C (zh) 2005-02-02
DE69633180D1 (de) 2004-09-23
PT835137E (pt) 2004-12-31
NO321427B1 (no) 2006-05-08
JP2008101011A (ja) 2008-05-01
EP0835137A1 (en) 1998-04-15
NO975813L (no) 1998-02-23
JP4848348B2 (ja) 2011-12-28
UA65525C2 (en) 2004-04-15
JP4119952B2 (ja) 2008-07-16
US6776985B1 (en) 2004-08-17
IL122119A0 (en) 1998-04-05
SI0835137T1 (sl) 2006-04-30
CA2222559A1 (en) 1997-01-16
PL324289A1 (en) 1998-05-11
NO975813D0 (no) 1997-12-10
WO1997001357A1 (en) 1997-01-16
ATE309000T1 (de) 2005-11-15
CN1189104A (zh) 1998-07-29

Similar Documents

Publication Publication Date Title
JP4848348B2 (ja) ウイルス粒子産生カプセル化細胞
JP4190579B2 (ja) 非分裂細胞への核酸運搬のためのベクターおよび使用方法
JP5956709B2 (ja) 遺伝子ベクター
TW201443233A (zh) 微泡及其製造方法
RU2185821C2 (ru) Трансдуцирующие цитохром р450 ретровирусные векторы
DE69619683T2 (de) Expression von heterologen genen in menschlichen brustzellen, einschliesslich menschliche brustkarzionomzellen unter der kontrolle von regulatorischen sequenzen von wap oder mmtv
JPH11514209A (ja) 組換えレトロウイルス調製物による造血幹細胞の高効率エクスビボ形質導入
JP2000500986A (ja) レトロウイルスベクターおよび遺伝子治療におけるその用途
Saller et al. Encapsulated cells producing retroviral vectors for in vivo gene transfer
AU724537C (en) Method for gene transfer to the central nervous system
JP4509780B2 (ja) 改変した細胞結合活性を有するウィルス粒子の調製方法およびその使用
HK1010139B (en) Encapsulated cells producing viral particles
US6540995B1 (en) Encapsulated cells producing cytochrome P450
US7074398B1 (en) Retroviral vectors carrying senescent cell derived inhibitors 1 (SDI-1)or antisense SDI-1 nucleotide sequences
EP0859854B1 (en) Retroviral vectors carrying senescent cell derived inhibitors 1 (sdi-1) or antisense sdi-1 nucleotide sequences
D’INHIBITEURS et al. ANTISENSE SDI-1 NUCLEOTIDE SEQUENCES
WO1996029423A1 (en) Compositions and methods for inducing infection by retroviral vectors outside of their host range

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110625